https://www.thebodypro.com/category/hiv-treatment-strategies/tag/conference-coverage
HIV Treatment Strategies

Conference Coverage

The Latest

Dolutegravir Superior in Women-Only Study Img

Dolutegravir Superior in Women-Only Study

On behalf of IFARA, Fred Schaich spoke with Kimberly Smith of ViiV Healthcare at this year's International AIDS Conference about 48-week data from the ARIA study of drug efficacy in women with HIV.

Promo Image

Update on Genetic Engineering for an HIV Cure

Genome engineering is an experimental approach for achieving a functional cure of HIV by genetically engineering CD4 T cells to become resistant to HIV, Paula Cannon, Ph.D., of the University of Southern California explained during a presentation at AS…

Lead author Esteban Martinez, M.D., Ph.D., presents his study results.

Taking Atripla Three Days a Week Maintains Undetectable HIV Viral Load, Pilot Study Finds

Taking efavirenz/tenofovir/emtricitabine (Atripla) three days a week maintained an undetectable viral load for at least 24 weeks in people who were already virally suppressed for at least two years, according to a small proof-of-concept study present...

PrEP, HIV Treatment and Social Determinants: Key Highlights From CROI 2016 Img

PrEP, HIV Treatment and Social Determinants: Key Highlights From CROI 2016

CROI 2016 provided a bevy of exciting updates in HIV prevention and treatment, with important developments in new PrEP modalities and sobering modeling of the current state of the epidemic.

Long-Acting Injectable HIV Treatment Safe and Effective at 32 Weeks Img

Long-Acting Injectable HIV Treatment Safe and Effective at 32 Weeks

Taking a long-acting injection of cabotegravir + rilpivirine (Edurant) either every four or eight weeks is safe and well tolerated while also maintaining high viral suppression rates, according to a CROI 2016 study.

CDC Highlights From the Conference on Retroviruses and Opportunistic Infections 2016 Img

CDC Highlights From the Conference on Retroviruses and Opportunistic Infections 2016

U.S. CDC scientists presented more than 40 abstracts at CROI 2016 that highlighted new HIV research findings and its implications for HIV prevention efforts across the nation.

What Can We Learn From HIV-Positive Patients Who Control the Virus After Stopping Treatment? Img

What Can We Learn From HIV-Positive Patients Who Control the Virus After Stopping Treatment?

In this interview, Matthew Perkins, M.D., discusses the interest in post-treatment controllers -- people living with HIV who are able to control the virus for a period of time after stopping therapy -- and the first study such individuals.

The Challenges of Assessing Guideline Adherence in a Rapidly Changing Treatment Landscape Img

The Challenges of Assessing Guideline Adherence in a Rapidly Changing Treatment Landscape

With more than 20 approved HIV antiretrovirals in the United States, physicians have many options for their patients -- they can choose one of the "preferred" drug regimens or deviate from treatment guidelines entirely.

Health Outcomes Worse for HIV-Positive Black Men Even Despite Equal Access Img

Health Outcomes Worse for HIV-Positive Black Men Even Despite Equal Access

A new study finds significant health disparities between black and white men with HIV, even though these men had equal access to health care through the Veterans Administration (VA).

Women and HIV: Same Treatment, Different Care Img

Women and HIV: Same Treatment, Different Care

Women with HIV should receive not only the same antiretroviral therapy as men, but also clinical care tailored to their specific risk factors and health care goals, according to Kathleen Squires, M.D.